用于癌症重新靶向的表达嵌合抗原受体的自然杀伤细胞
CAR-Expressing Natural Killer Cells for Cancer Retargeting.
作者信息
Kloess Stephan, Kretschmer Anna, Stahl Lilly, Fricke Stephan, Koehl Ulrike
机构信息
Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany.
Institute for Cellular Therapeutics, ATMP-GMPDU, Hannover Medical School, Hannover, Germany.
出版信息
Transfus Med Hemother. 2019 Feb;46(1):4-13. doi: 10.1159/000495771. Epub 2019 Feb 5.
Abstract
Since the approval in 2017 and the outstanding success of Kymriah® and Yescarta®, the number of clinical trials investigating the safety and efficacy of chimeric antigen receptor-modified autologous T cells has been constantly rising. Currently, more than 200 clinical trials are listed on clinicaltrial.gov. In contrast to CAR-T cells, natural killer (NK) cells can be used from allogeneic donors as an "off the shelf product" and provide alternative candidates for cancer retargeting. This review summarises preclinical results of CAR-engineered NK cells using both primary human NK cells and the cell line NK-92, and provides an overview about the first clinical CAR-NK cell studies targeting haematological malignancies and solid tumours, respectively.
摘要
自2017年Kymriah®和Yescarta®获批且取得显著成功以来，研究嵌合抗原受体修饰的自体T细胞安全性和有效性的临床试验数量一直在不断增加。目前，clinicaltrial.gov上列出了200多项临床试验。与CAR-T细胞不同，自然杀伤（NK）细胞可作为“现成产品”从异体供体获取，为癌症重定向提供了替代候选方案。本综述总结了使用原代人NK细胞和NK-92细胞系的CAR工程化NK细胞的临床前结果，并分别概述了针对血液系统恶性肿瘤和实体瘤的首批CAR-NK细胞临床研究。
相似文献
1
CAR-Expressing Natural Killer Cells for Cancer Retargeting.用于癌症重新靶向的表达嵌合抗原受体的自然杀伤细胞
Transfus Med Hemother. 2019 Feb;46(1):4-13. doi: 10.1159/000495771. Epub 2019 Feb 5.
2
Chimeric Antigen Receptor-Natural Killer Cells: A New Breakthrough in the Treatment of Solid Tumours.嵌合抗原受体自然杀伤细胞：实体瘤治疗的新突破。
Clin Oncol (R Coll Radiol). 2023 Mar;35(3):153-162. doi: 10.1016/j.clon.2022.10.019. Epub 2022 Nov 24.
3
CAR-expressing NK cells for cancer therapy: a new hope.嵌合抗原受体 NK 细胞治疗肿瘤：新希望。
Biosci Trends. 2020 Nov 4;14(5):354-359. doi: 10.5582/bst.2020.03308. Epub 2020 Sep 6.
4
Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review).嵌合抗原受体自然杀伤细胞：实体瘤免疫治疗的新见解（综述）
Exp Ther Med. 2021 Apr;21(4):340. doi: 10.3892/etm.2021.9771. Epub 2021 Feb 10.
5
Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.嵌合抗原受体肿瘤免疫治疗的改革：重定向自然杀伤细胞。
Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):200-215. doi: 10.1016/j.bbcan.2018.01.005. Epub 2018 Jan 31.
6
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.嵌合抗原受体表达的自然杀伤细胞用于癌症的免疫治疗。
Front Immunol. 2018 Feb 15;9:283. doi: 10.3389/fimmu.2018.00283. eCollection 2018.
7
Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.嵌合抗原受体自然杀伤细胞为基础的"现货"急性髓系白血病免疫疗法的合适自然杀伤细胞来源的临床前评估。
Hum Gene Ther. 2019 Apr;30(4):381-401. doi: 10.1089/hum.2018.247. Epub 2019 Mar 18.
8
Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.自然杀伤细胞亚群的内在功能潜能限制了嵌合抗原受体驱动的重定向。
Cancer Immunol Res. 2018 Apr;6(4):467-480. doi: 10.1158/2326-6066.CIR-17-0207. Epub 2018 Feb 19.
9
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity.嵌合抗原受体工程化NK-92细胞：一种用于靶向消除癌细胞和诱导保护性抗肿瘤免疫的现成细胞疗法。
Front Immunol. 2017 May 18;8:533. doi: 10.3389/fimmu.2017.00533. eCollection 2017.
10
From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies.从嵌合抗原受体T细胞到嵌合抗原受体自然杀伤细胞：一种用于血液系统恶性肿瘤的新兴免疫治疗方法。
Front Oncol. 2021 Aug 6;11:720501. doi: 10.3389/fonc.2021.720501. eCollection 2021.
引用本文的文献
1
CAR-NK, a Splendid Strategy for Cancer, Especially for Gynecologic Tumor.嵌合抗原受体自然杀伤细胞疗法（CAR-NK），一种治疗癌症的卓越策略，尤其适用于妇科肿瘤。
Immun Inflamm Dis. 2025 Jun;13(6):e70210. doi: 10.1002/iid3.70210.
2
Evaluating the Influence of Different Serum-Free Culture Conditions on the Production and Function of Natural Killer Cell-Derived Extracellular Vesicles.评估不同无血清培养条件对自然杀伤细胞衍生细胞外囊泡产生及功能的影响。
J Extracell Biol. 2025 Apr 25;4(4):e70049. doi: 10.1002/jex2.70049. eCollection 2025 Apr.
3
Prospects for potential therapy targeting immune‑associated factors in endometriosis (Review).针对子宫内膜异位症中免疫相关因子的潜在治疗前景（综述）
Mol Med Rep. 2025 Mar;31(3). doi: 10.3892/mmr.2024.13422. Epub 2024 Dec 24.
4
Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery.非病毒方法在 CAR-NK 细胞工程中的应用：连接自然杀伤细胞生物学和基因传递。
J Nanobiotechnology. 2024 Sep 10;22(1):552. doi: 10.1186/s12951-024-02746-4.
5
Augmenting the Antitumor Efficacy of Natural Killer Cells via SynNotch Receptor Engineering for Targeted IL-12 Secretion.通过合成Notch受体工程靶向分泌白细胞介素-12增强自然杀伤细胞的抗肿瘤功效
Curr Issues Mol Biol. 2024 Mar 28;46(4):2931-2945. doi: 10.3390/cimb46040183.
6
A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases.一种新的观点，认为 CAR-NK 和 CAR-T 细胞在治疗癌症和自身免疫性疾病方面都具有疗效。
Med Oncol. 2024 Apr 24;41(6):127. doi: 10.1007/s12032-024-02362-0.
7
Reovirus infection of tumor cells reduces the expression of NKG2D ligands, leading to impaired NK-cell cytotoxicity and functionality.呼肠孤病毒感染肿瘤细胞会降低 NKG2D 配体的表达，从而导致 NK 细胞的细胞毒性和功能受损。
Front Immunol. 2023 Sep 11;14:1231782. doi: 10.3389/fimmu.2023.1231782. eCollection 2023.
8
The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors.将嵌合抗原受体 T 细胞（CAR-T 细胞）引入大脑所面临的特殊挑战：在临床应用于治疗儿科中枢神经系统肿瘤方面的观点。
Front Immunol. 2023 Mar 21;14:1142597. doi: 10.3389/fimmu.2023.1142597. eCollection 2023.
9
Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting.NK 细胞治疗血液系统恶性肿瘤的研究进展：NK 细胞来源、持久性和肿瘤靶向性。
Blood Rev. 2023 Jul;60:101073. doi: 10.1016/j.blre.2023.101073. Epub 2023 Mar 12.
10
Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B.通过基因修饰使 NK 细胞表达趋化因子受体 CCR4 和 CCR2B 实现高效重定向。
Int J Mol Sci. 2023 Feb 4;24(4):3129. doi: 10.3390/ijms24043129.
本文引用的文献
1
Making CAR T Cells a Solid Option for Solid Tumors.将 CAR T 细胞疗法变为实体瘤的可靠选择。
Front Immunol. 2018 Nov 8;9:2593. doi: 10.3389/fimmu.2018.02593. eCollection 2018.
2
Clinical use of lentiviral vectors.慢病毒载体的临床应用。
Leukemia. 2018 Jul;32(7):1529-1541. doi: 10.1038/s41375-018-0106-0. Epub 2018 Mar 22.
3
Advances in immunotherapy for acute myeloid leukemia.急性髓系白血病的免疫疗法进展。
Future Oncol. 2018 Apr;14(10):963-978. doi: 10.2217/fon-2017-0459. Epub 2018 Mar 15.
4
Investigational CD33-targeted therapeutics for acute myeloid leukemia.针对急性髓细胞白血病的 CD33 靶向治疗药物的研究。
Expert Opin Investig Drugs. 2018 Apr;27(4):339-348. doi: 10.1080/13543784.2018.1452911. Epub 2018 Mar 15.
5
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.嵌合抗原受体表达的自然杀伤细胞用于癌症的免疫治疗。
Front Immunol. 2018 Feb 15;9:283. doi: 10.3389/fimmu.2018.00283. eCollection 2018.
6
T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G.T细胞浸润尤因肉瘤与免疫抑制性HLA-G的局部表达有关。
Oncotarget. 2017 Dec 22;9(5):6536-6549. doi: 10.18632/oncotarget.23815. eCollection 2018 Jan 19.
7
Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.自然杀伤细胞亚群的内在功能潜能限制了嵌合抗原受体驱动的重定向。
Cancer Immunol Res. 2018 Apr;6(4):467-480. doi: 10.1158/2326-6066.CIR-17-0207. Epub 2018 Feb 19.
8
CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.不同共刺激分子的 CD33 特异性嵌合抗原受体 T 细胞表现出强大的抗白血病疗效和不同的表型。
Hum Gene Ther. 2018 May;29(5):626-639. doi: 10.1089/hum.2017.241. Epub 2018 Mar 19.
9
Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines.利用自然杀伤细胞（NK）和经CRISPR编辑的T细胞系中两个结构不同的抗CD5抗原结合域开发靶向T细胞恶性肿瘤的嵌合抗原受体。
Oncoimmunology. 2017 Dec 26;7(3):e1407898. doi: 10.1080/2162402X.2017.1407898. eCollection 2018.
10
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.替沙格赛定用于治疗儿童和年轻成人B细胞淋巴细胞白血病
N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.
Zotero 插件